Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (NCT04140500)
An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluate preliminary anti-tumor activity in participants with solid tumors. An expansion part of the study is planned to enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RP2D of RO7247669 and to confirm safety and tolerability in participants with selected tumor types.
Who can join: Review the eligibility criteria below.
Location: Rigshospitalet — København Ø
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Rigshospitalet — København Ø,
- Odense Universitetshospital, Onkologisk Afdeling R — Odense C,
- LLC Arensia Explorer Medicine — Tbilisi,
- Hadassah University Hospital - Ein Kerem — Jerusaelm,
- Rabin MC — Petah Tikva,
- Chaim Sheba medical center, Oncology division — Ramat Gan,
- Hospital Civil de Guadalajara Fray Antonio Alcalde — Guadalajara, Jalisco
- Inst. Nacional de Cancerología — Mexico City, Mexico CITY (federal District)
- Consultorio Médico Jordi Guzmán Casta — Querétaro City, Querétaro
- National University Hospital — Singapore,
- National Cancer Centre — Singapore,
- Seoul National University Bundang Hospital — Seongnam-si,
- Severance Hospital, Yonsei University Health System — Seoul,
- Asan Medical Center — Seoul,
- Clinica Universitaria de Navarra — Pamplona, Navarre
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona — Barcelona,
- Clinica Universidad de Navarra Madrid — Madrid,
- START Madrid-FJD, Hospital Fundacion Jimenez Diaz — Madrid,
- START Madrid. Centro Integral Oncologico Clara Campal — Madrid,
- Adana City Hospital, Medical Oncology — Adana,
- Ankara City Hospital — Ankara,
- Hacettepe Uni Medical Faculty Hospital — Sihhiye/Ankara,
- Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center — Yen?mahalle,
- Queen Elizabeth Hospital — Birmingham,
- Christie Hospital NHS Trust — Manchester,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.